Gengos Andrew 4

What Happened Andrew Gengos, a director of Turn Therapeutics (TTRX), was granted a derivative award covering 95,000 shares on June 4, 2026. The filing lists the acquisition price as $0.00 (derivative award), so no cash changed hands at grant; this is a compensation grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-04; Form 4 filed: 2026-06-08.
• Transaction type: Award/Grant (derivative); amount: 95,000 shares; price shown: $0.00; total shown: $0.
• Vesting: The award vests in twelve (12) equal monthly installments, on the last day of each calendar month, beginning June 30, 2026, subject to continued service and plan terms (per footnote).
• Shares owned after the transaction: not specified in the provided excerpt.
• Timeliness: filing date is four days after the transaction; Form 4s are generally due within two business days, so investors may note the gap.

Context This was an equity award (derivative grant) as part of compensation or board-related incentives, not a market purchase or sale. Such grants are common for executives and directors and typically vest over time to align incentives; they do not by themselves indicate an immediate buy or sell decision.